TRACON Pharmaceuticals (TCON)
(Delayed Data from NSDQ)
$1.52 USD
+0.02 (1.33%)
Updated May 23, 2024 04:00 PM ET
After-Market: $1.54 +0.02 (1.32%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
TRACON Pharmaceuticals, Inc. [TCON]
Reports for Purchase
Showing records 61 - 70 ( 70 total )
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Another Validation for TRC105, Data from Four Phase 2''s Coming Up
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Intriguing Entry Point Ahead of Data Deluge
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Intriguing Play in the $16B Global Anti-VEGF Market-Initiate with Buy rating and $18 target
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D